Concepedia
Statistics
Publications
22
Citations
3.7K
H-Index
17
Active since
2008
Affiliations
Pfizer (United States)(Current)
Institut Gustave Roussy
Peter MacCallum Cancer Centre
Massachusetts General Hospital
Pfizer (Italy)
Jill S. Clancy is an author at Pfizer (United States) specializing in medicine, oncology, and medical oncology.
Publications per year
2008–2021
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin Solomon, Benjamin Besse, Todd M. Bauer et al. · The Lancet Oncology · 2018 · 789 citations
Medicine, Oncology, Medical Oncology +10
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T. Shaw, Enriqueta Felip, Todd M. Bauer et al. · The Lancet Oncology · 2017 · 649 citations · Full text
Medicine, Oncology, Pharmacology +14
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Raoul Herbrecht, Jorge Romaguera, Gregor Verhoef et al. · Journal of Clinical Oncology · 2009 · 640 citations
Pharmacy, Oncology, Pharmacotherapy +11
<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer
Alice T. Shaw, Benjamin Solomon, Benjamin Besse et al. · Journal of Clinical Oncology · 2019 · 379 citations · Full text
Medicine, Oncology, Pharmacology +17
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
Alice T. Shaw, Benjamin Solomon, Rita Chiari et al. · The Lancet Oncology · 2019 · 352 citations
Medicine, Oncology, Pharmacology +11
1–5 of 22